Literature DB >> 8274908

Oral cholera vaccine well tolerated.

P Barrett, P Clarke, S Cryz.   

Abstract

Mesh：

Substances：

Year:  1993        PMID： 8274908      PMCID： PMC1679635          DOI： 10.1136/bmj.307.6916.1425-b

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  3 in total

1.  Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial.

Authors:  K L Kotloff; S S Wasserman; S O'Donnell; G A Losonsky; S J Cryz; M M Levine
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

2.  Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR.

Authors:  M M Levine; J B Kaper; D Herrington; J Ketley; G Losonsky; C O Tacket; B Tall; S Cryz
Journal:  Lancet       Date:  1988-08-27       Impact factor: 79.321

3.  Randomized double-blind placebo controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in Swiss adults.

Authors:  S J Cryz; M M Levine; J B Kaper; E Fürer; B Althaus
Journal:  Vaccine       Date:  1990-12       Impact factor: 3.641
  3 in total
  2 in total

1.  Randomized, double-blind placebo-controlled trial to evaluate the safety and immunogenicity of combined Salmonella typhi Ty21a and Vibrio cholerae CVD 103-HgR live oral vaccines.

Authors:  H Kollaritsch; E Furer; C Herzog; G Wiedermann; J U Que; S J Cryz
Journal:  Infect Immun       Date:  1996-04       Impact factor: 3.441

2.  Safety and immunogenicity of a live oral bivalent typhoid fever (Salmonella typhi Ty21a)-cholera (Vibrio cholerae CVD 103-HgR) vaccine in healthy adults.

Authors:  S J Cryz; J U Que; M M Levine; G Wiedermann; H Kollaritsch
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.